Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT02681991
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Registry
-
NCT02681991
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02681991. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2016-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
- Condition
- Chronic Renal Failure
- Intervention (Drug)
- Renamezin capsule
- Lead sponsor
- Daewon Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct02681991- Content hash
b143fbed2e7174f47dc58e72bd3763f996407c5b5699827d3e57b6b9a897870a